CXCR4 and myocardial infarction: Indeed, several CXCR4 small-molecule antagonists, including AMD3100, TG-0054, POL6326 and POL5551, appear to meet these requirements and have been shown to enhance tissue repair and improve cardiac function after myocardial infarction as demonstrated in AMI animal models [10,11,23,24,25].